United States — Food and Drug Administration & Peretz Bronstein

United States — Food and Drug Administration: The United States — Food and Drug Administration issued a Complete Response Letter to Aldeyra Therapeutics, citing a lack of substantial evidence for the efficacy of reproxalap, which triggered the stock price drop and subsequent lawsuits.

Peretz Bronstein: Peretz Bronstein is a founding partner of Bronstein, Gewirtz & Grossman, LLC, actively involved in the class action lawsuit against Aldeyra Therapeutics.

United States — Food and Drug Administration: The United States — Food and Drug Administration issued safety warnings concerning serious neurological complications in dogs related to Zoetis' Bedinvetmab, contributing to its weakening adoption.

Peretz Bronstein: Peretz Bronstein is the Founding Partner of Bronstein, Gewirtz & Grossman, LLC, a firm actively involved in the class action lawsuit against Zoetis.

United States — Food and Drug Administration: The FDA rejected Replimune's BLA and published briefing documents raising concerns about the data package, triggering the stock drop and subsequent lawsuits. The FDA's actions are central to the event.

Peretz Bronstein: Peretz Bronstein is the founding partner of Bronstein, Gewirtz & Grossman, LLC and is named as a contact for the class action. His role is to represent investors and promote the lawsuit, but he is not directly affected by the event.

United States — Food and Drug Administration: The FDA placed a full clinical hold on ARD-101's IND, halting all ongoing studies. This regulatory action is central to the lawsuit and has severely impacted Aardvark's operations and stock price.

Peretz Bronstein: Peretz Bronstein is the founding partner of Bronstein, Gewirtz & Grossman, LLC and is involved in the class action. His role is to represent investors and seek recovery.

United States — Food and Drug Administration: Regulator whose briefing documents and advisory committee vote triggered the stock collapse and legal actions.

Peretz Bronstein: Founding partner at Bronstein, Gewirtz & Grossman involved in the lawsuit.

United States — Food and Drug Administration: The United States — Food and Drug Administration issued a warning letter to ImmunityBio regarding misleading efficacy claims made by Patrick Soon-Shiong about Anktiva, which triggered the stock price drop and subsequent lawsuits.

Peretz Bronstein: Peretz Bronstein is a founding partner of Bronstein, Gewirtz & Grossman, LLC, which has filed a class action lawsuit against ImmunityBio.